J-LSMS | Abstracts | 2020 Annual LaACP Meeting

Table 1

Patient Characteristics

Event-Positive Patients (n=11)

Event-Negative Patients (n=15)

Mean, No. (%)

±SD 9.38

Mean, No. (%)

±SD 9.69

P-value

Age

57.64

60.67

0.43 0.43

Male sex

5/11 (45%)

10/15 (66%)

Underlying comorbidities

Hypertension

7/11 (64%) 5/11 (45%) 1/11 (9%)

10/15 (67%) 7/15 (47%) 3/15 (20%) 1/15 (7%) 4/15 (27%) 7/15 (47%) 5/15 (33%) 12/15 (80%) 13/15 (87%) 13/15 (87%) 14/15 (93%) 13/15 (87%) 4/15 (27%) 14/15 (93%)

1 1

Diabetes Mellitus

Coronary artery disease Congestive Heart Failure Chronic Kidney Disease

0.61

0/11 0/11

1

0.11

Predominant presenting symptoms Hypoxemia and/or SOB

7/11 (64%) 8/11 (73%) 9/11 (82%) 7/11 (64%)

0.45 0.11

Fever

Mechanical Ventilation Dexmedetomidine Hydroxychloroquine

1

0.35 0.49

11/11 (100%) 10/11 (91%) 11/11 (100%)

Azithromycin Anticoagulation

1

0.49 0.68

AV-nodal blockers and AADs Qualitative Troponin I assessment

4/11 (36%) 9/11 (82%)

1

Peak Troponin I, ng/mL

2.72 7703 23.98

4.48

0.42 1905 20.24

0.52 2422 11.52

0.07 0.16 0.38 0.85 0.29 0.84 0.51 0.82

NT-ProBNP, pg/mL

12995

Peak C-reactive protein, mg/dL

9.07

D-dimer, ng/mL

4128.91

1609.63 112.84

3996.36

1756.95

Peak Procalcitonin, ng/mL

42.15 83.45

10.31 84.62

15.87 16.82 29.23 36.12

QRS duration (ms) PR Interval (ms) QTc interval (ms)

8.86

148.55

21.37

155.69 462.69

458

59.6

Deceased 0.78 Abbreviations: SD, standard deviation; AV, atrioventricular; AAD, antiarrhythmic drugs; NT-ProBNP, N-terminal-proB-type natriuretic peptide SI conversion factors: To convert Troponin I to µg/L, multiply by 1; NT-ProBNP to pmol/L, multiply by 0.1182; C-reactive protein to mg/L, multiply by 10; D-dimer to µg/L, multiply by 1; Procalcitonin to ng/L, multiply by 1000. 5/11 (45%) 6/15 (40%)

Made with FlippingBook Digital Publishing Software